BELLUS Health Inc. is a biopharmaceutical firm in the clinical development... BELLUS Health Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to creating new therapeutic options for intractable chronic cough (RCC) and various other conditions characterized by heightened cough sensitivity. The company's primary investigational compound, BLU-5937, functions as a P2X3 receptor antagonist. This drug is currently progressing through Phase II clinical trials, where it is being assessed for its potential in treating both RCC and persistent itching. Founded in 1993, BELLUS Health Inc. is headquartered in Laval, Canada.
